Seikagaku Corporation (4548)
JPX JPX Primary Summary
Seikagaku Corporation (4548) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Seikagaku Corporation ever had a stock split?
Seikagaku Corporation Profile
| Pharmaceuticals Industry | Healthcare Sector | Mr. Kenji Mizutani CEO | JPX Exchange | JP3414000004 ISIN |
| Japan Country | 1,075 Employees | 29 Sep 2026 Last Dividend | 28 Mar 2005 Last Split | - IPO Date |
Overview
Seikagaku Corporation is a Tokyo-based company entrenched in the healthcare sector, with a focus on manufacturing and distributing pharmaceuticals and medical devices across the globe. The core of its offerings revolves around glycoconjugates, a class of biologically significant molecules. Established in 1947 and initially known as K.K. Seikagaku Kenkyusho, the company rebranded to its current name in 1962. With operations divided into two primary segments—Pharmaceuticals and LAL Business—Seikagaku Corporation stands as a significant player in its domain, driven by innovation and a commitment to improving health outcomes.
Products and Services
Seikagaku Corporation’s portfolio is broad, catering to various healthcare needs through its Pharmaceuticals and LAL Business segments:
- Intra-articular Injections: Products like ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX are designed to enhance joint functions, offering relief and improved mobility for patients with joint-related conditions.
- Ophthalmic Surgical Aids: Under the OPEGAN and SHELLGAN brands, these aids facilitate ophthalmic surgeries, enhancing safety and efficiency during procedures.
- Surgical Aids for Endoscopic Mucosal Resection: MucoUp is a specialized product aiding in the delicate process of endoscopic mucosal resection, improving outcomes and safety for gastrointestinal surgeries.
- Treatment for Lumbar Disc Herniation: HERNICORE is specifically formulated to address the challenging condition of lumbar disc herniation, offering a non-surgical treatment option to alleviate symptoms.
- Bulk Products: Essential biochemicals like sodium hyaluronate and sodium chondroitin sulfate are offered for use in pharmaceuticals and cosmetics, highlighting the company’s versatility and commitment to broad-sector support.
- Endotoxin-Detecting Reagents: Brands such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc., are pivotal in the quality control processes for injectable pharmaceuticals and medical devices, as well as for water quality control in dialysis processes.
Additionally, Seikagaku Corporation is actively engaged in the development of new therapies and solutions, including SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for knee osteoarthritis; SI-722 for interstitial cystitis and bladder pain syndrome; SI-613-ETP for enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. These advancements embody the company's pioneering spirit and dedication to addressing unmet medical needs.
